M. McKenzie

A first-in-human phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3K inhibitor GDC-0941, in patients with advanced solid tumors.

M. Belvin, G. Shapiro, P. LoRusso, 2012 .

Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A first-in-human phase Ib study testing daily and intermittent dosing schedules in patients with advanced solid tumors.

C. Jones, A. D. de Crespigny, M. Belvin, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract LB-89: Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A first-in-human phase Ib study in patients with advanced solid tumors

M. Belvin, G. Shapiro, P. LoRusso, 2011 .

Drug precipitation within i.v. tubing: a potential hazard of chemotherapy administration.

M. Citron, M. Cohen, S. Krasnow, 1985, Cancer treatment reports.

Myths about diversity in clinical trials reduce return on investment for industry

N. Kolatkar, Shilpen A. Patel, N. Richie, 2022, Nature Medicine.